相关实验视频

Updated: Aug 4, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

RBM47是一种新型免疫治疗标,也是质瘤的预后生物标志物

Wei Wei1, Yongfu Cao2, Xin Lu3

  • 1Department of Neurosurgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Street, Nanchang, 330006, Jiangxi, China.

Scientific reports
|January 5, 2025
PubMed
概括

RNA结合蛋白47 (RBM47) 在质瘤中升高,并与患者预后不佳有关. RBM47影响瘤免疫微环境,可能成为新型质瘤免疫疗法的标.

关键词:
质瘤是一种质瘤.免疫微环境是一个微环境.免疫治疗是一种免疫疗法.巨细胞是一个巨细胞.这是一个RBM4747的标志.

更多相关视频

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.8K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.